Background Recent cases of clinical failure in malaria patients in the United Kingdom (UK)
treated with artemether-lumefantrine have implications for malaria chemotherapy worldwide …

We present case histories of four patients treated with artemether-lumefantrine for falciparum
malaria in UK hospitals in 2015 to 2016. Each subsequently presented with recurrent …

The failure of artemisinin combination therapy (ACT) in malaria patients returning from
endemic regions may be driven by parasite resistance to this treatment. ACT is used globally …

Background Artemether-lumefantrine (AL) is a major and highly effective artemisinin-based
combination therapy that is becoming increasingly important as a new first-line therapy …

Artemether-lumefantrine is currently first-line therapy of Plasmodium falciparum malaria in
many countries. This report describes a treatment failure despite adequate drug …

In Uganda, artemether-lumefantrine was introduced as an artemisinin-based combination
therapy (ACT) for malaria in 2006. We have previously reported a moderate decrease in ex …

Background Failure of artemisinin-based combination therapy is increasingly reported in
patients with Plasmodium falciparum malaria in sub-Saharan Africa. We aimed to describe …

Artemisinin derivative–based combination therapy is expected to suppress the development
of Plasmodium falciparum drug resistance in Africa. We have performed an artemether …

Background. Artemisinin-based combination therapy (ACT) is the first-line treatment of
Plasmodium falciparum malaria. Since the introduction of artemether-lumefantrine (AL) for …

Artemisinin partial resistance may facilitate selection of Plasmodium falciparum resistant to
combination therapy partner drugs. We evaluated 99 P. falciparum isolates collected in 2021 …